Amedeo Smart

Free Medical Literature Service

 

Amedeo

Prostate Cancer
  Free Subscription

Articles published in
Cancer Imaging
    October 2024
  1. BURGARD C, Rosar F, Larsen E, Khreish F, et al
    Outstanding increase in tumor-to-background ratio over time allows tumor localization by [(89)Zr]Zr-PSMA-617 PET/CT in early biochemical recurrence of prostate cancer.
    Cancer Imaging. 2024;24:132.
    >> Share

    September 2024
  2. VENTURA D, Rassek P, Schindler P, Akkurt BH, et al
    Early treatment response assessment with [(177)Lu]PSMA whole-body-scintigraphy compared to interim PSMA-PET.
    Cancer Imaging. 2024;24:126.
    >> Share

    August 2024
  3. HARSINI S, Martineau P, Plaha S, Saprunoff H, et al
    Prognostic significance of a negative PSMA PET/CT in biochemical recurrence of prostate cancer.
    Cancer Imaging. 2024;24:117.
    >> Share

  4. XU L, Peng Q, Zhang G, Zhang D, et al
    Development of preoperative nomograms to predict the risk of overall and multifocal positive surgical margin after radical prostatectomy.
    Cancer Imaging. 2024;24:104.
    >> Share

    July 2024
  5. FURMAN B, Falick Michaeli T, Den R, Ben Haim S, et al
    Pelvic lymph node mapping in prostate cancer: examining the impact of PSMA PET/CT on radiotherapy decision-making in patients with node-positive disease.
    Cancer Imaging. 2024;24:96.
    >> Share

  6. KALLIS K, Conlin CC, Zhong AY, Hussain TS, et al
    Comparison of synthesized and acquired high b-value diffusion-weighted MRI for detection of prostate cancer.
    Cancer Imaging. 2024;24:89.
    >> Share

  7. YANG J, Xiao L, Zhou M, Li Y, et al
    [(68)Ga]Ga?PSMA?617 PET-based radiomics model to identify candidates for active surveillance amongst patients with GGG 1-2 prostate cancer at biopsy.
    Cancer Imaging. 2024;24:86.
    >> Share

  8. GROSS M, Eisenhuber E, Assinger P, Schima R, et al
    MRI-guided in-bore biopsy of the prostate - defining the optimal number of cores needed.
    Cancer Imaging. 2024;24:81.
    >> Share

    May 2024
  9. AYATI N, McIntosh L, Buteau J, Alipour R, et al
    Comparison of quantitative whole body PET parameters on [(68)Ga]Ga-PSMA-11 PET/CT using ordered Subset Expectation Maximization (OSEM) vs. bayesian penalized likelihood (BPL) reconstruction algorithms in men with metastatic castration-resistant prosta
    Cancer Imaging. 2024;24:57.
    >> Share

    April 2024
  10. KOLADE OU, Brink A, Ayeni AO, More S, et al
    Optimizing PSMA scintigraphy for resource limited settings - a retrospective comparative study.
    Cancer Imaging. 2024;24:46.
    >> Share

    February 2024
  11. YAZDANI E, Karamzadeh-Ziarati N, Cheshmi SS, Sadeghi M, et al
    Automated segmentation of lesions and organs at risk on [(68)Ga]Ga-PSMA-11 PET/CT images using self-supervised learning with Swin UNETR.
    Cancer Imaging. 2024;24:30.
    >> Share

  12. ROSAR F, Burgard C, Larsen E, Khreish F, et al
    [(89)Zr]Zr-PSMA-617 PET/CT characterization of indeterminate [(68)Ga]Ga-PSMA-11 PET/CT findings in patients with biochemical recurrence of prostate cancer: lesion-based analysis.
    Cancer Imaging. 2024;24:27.
    >> Share

  13. GUERRA A, Orton MR, Wang H, Konidari M, et al
    Clinical application of machine learning models in patients with prostate cancer before prostatectomy.
    Cancer Imaging. 2024;24:24.
    >> Share

  14. HU C, Qiao X, Hu C, Cao C, et al
    The practical clinical role of machine learning models with different algorithms in predicting prostate cancer local recurrence after radical prostatectomy.
    Cancer Imaging. 2024;24:23.
    >> Share

    January 2024
  15. MA Y, Gao F
    Advances of radiolabeled GRPR ligands for PET/CT imaging of cancers.
    Cancer Imaging. 2024;24:19.
    >> Share

    December 2023
  16. DONNERS R, Figueiredo I, Westaby D, Koh DM, et al
    Multiparametric bone MRI targeting aides lesion selection for CT-guided sclerotic bone biopsies in metastatic castrate resistant prostate cancer.
    Cancer Imaging. 2023;23:121.
    >> Share

    November 2023
  17. PENG Q, Xu L, Zhang G, Zhang D, et al
    Effect of preoperative PI-RADS assessment on pathological outcomes in patients who underwent radical prostatectomy.
    Cancer Imaging. 2023;23:113.
    >> Share

  18. LUO L, Zheng A, Chang R, Li Y, et al
    Evaluating the value of (18)F-PSMA-1007 PET/CT in the detection and identification of prostate cancer using histopathology as the standard.
    Cancer Imaging. 2023;23:108.
    >> Share

    September 2023
  19. HU B, Zhang H, Zhang Y, Jin Y, et al
    A nomogram based on biparametric magnetic resonance imaging for detection of clinically significant prostate cancer in biopsy-naive patients.
    Cancer Imaging. 2023;23:82.
    >> Share

  20. YANG J, Li J, Xiao L, Zhou M, et al
    (68)Ga-PSMA PET/CT-based multivariate model for highly accurate and noninvasive diagnosis of clinically significant prostate cancer in the PSA gray zone.
    Cancer Imaging. 2023;23:81.
    >> Share

    August 2023
  21. YU W, Zhao M, Deng Y, Liu S, et al
    Meta-analysis of (18) F-PSMA-1007 PET/CT, (18) F-FDG PET/CT, and (68)Ga-PSMA PET/CT in diagnostic efficacy of prostate Cancer.
    Cancer Imaging. 2023;23:77.
    >> Share

    June 2023
  22. TREMBLAY S, Alhogbani M, Weickhardt A, Davis ID, et al
    Influence of molecular imaging on patient selection for treatment intensification prior to salvage radiation therapy for prostate cancer: a post hoc analysis of the PROPS trial.
    Cancer Imaging. 2023;23:57.
    >> Share

    April 2023
  23. GUERRA A, Alves FC, Maes K, Joniau S, et al
    Correction: Early biomarkers of extracapsular extension of prostate cancer using MRI-derived semantic features.
    Cancer Imaging. 2023;23:32.
    >> Share

    March 2023
  24. HARSINI S, Wilson D, Saprunoff H, Allan H, et al
    Outcome of patients with biochemical recurrence of prostate cancer after PSMA PET/CT-directed radiotherapy or surgery without systemic therapy.
    Cancer Imaging. 2023;23:27.
    >> Share

    January 2023
  25. LIU X, Zhu Z, Wang K, Zhang Y, et al
    Semiautomated pelvic lymph node treatment response evaluation for patients with advanced prostate cancer: based on MET-RADS-P guidelines.
    Cancer Imaging. 2023;23:7.
    >> Share

  26. HU L, Fu C, Song X, Grimm R, et al
    Automated deep-learning system in the assessment of MRI-visible prostate cancer: comparison of advanced zoomed diffusion-weighted imaging and conventional technique.
    Cancer Imaging. 2023;23:6.
    >> Share

  27. LIU LL, Zhu LL, Lu ZG, Sun JD, et al
    Variability of radiotherapy volume delineation: PSMA PET/MRI and MRI based clinical target volume and lymph node target volume for high-risk prostate cancer.
    Cancer Imaging. 2023;23:1.
    >> Share

    December 2022
  28. WEI X, Zhu L, Zeng Y, Xue K, et al
    Detection of prostate cancer using diffusion-relaxation correlation spectrum imaging with support vector machine model - a feasibility study.
    Cancer Imaging. 2022;22:77.
    >> Share

  29. GUERRA A, Alves FC, Maes K, Joniau S, et al
    Early biomarkers of extracapsular extension of prostate cancer using MRI-derived semantic features.
    Cancer Imaging. 2022;22:74.
    >> Share

  30. REYNOLDS HM, Tadimalla S, Wang YF, Montazerolghaem M, et al
    Semi-quantitative and quantitative dynamic contrast-enhanced (DCE) MRI parameters as prostate cancer imaging biomarkers for biologically targeted radiation therapy.
    Cancer Imaging. 2022;22:71.
    >> Share

    October 2022
  31. ZHANG X, Hong H, Liang D
    The combined value of mpUS and mpMRI-TRUS fusion for the diagnosis of clinically significant prostate cancer.
    Cancer Imaging. 2022;22:60.
    >> Share

    September 2022
  32. GLEMSER PA, Rotkopf LT, Ziener CH, Beuthien-Baumann B, et al
    Hybrid imaging with [(68)Ga]PSMA-11 PET-CT and PET-MRI in biochemically recurrent prostate cancer.
    Cancer Imaging. 2022;22:53.
    >> Share

  33. DUAN H, Iagaru A
    The use of advanced imaging in guiding the further investigation and treatment of primary prostate cancer.
    Cancer Imaging. 2022;22:45.
    >> Share

    July 2022
  34. ZHANG YN, Lu ZG, Wang SD, Lu X, et al
    Gross tumor volume delineation in primary prostate cancer on (18)F-PSMA-1007 PET/MRI and (68)Ga-PSMA-11 PET/MRI.
    Cancer Imaging. 2022;22:36.
    >> Share

  35. RUCHALSKI K, Kim HJ, Douek M, Raman S, et al
    Pretreatment visceral metastases in castration resistant metastatic prostate cancer: role in prediction versus actual site of disease progression.
    Cancer Imaging. 2022;22:34.
    >> Share

    April 2022
  36. CHEN Z, Chen X, Wang R
    Application of SPECT and PET / CT with computer-aided diagnosis in bone metastasis of prostate cancer: a review.
    Cancer Imaging. 2022;22:18.
    >> Share

    March 2022
  37. LEWIS S, Ganti A, Argiriadi P, Rosen A, et al
    Prostate MRI using a rigid two-channel phased-array endorectal coil: comparison with phased array coil acquisition at 3 T.
    Cancer Imaging. 2022;22:15.
    >> Share

    September 2021
  38. XING P, Chen L, Yang Q, Song T, et al
    Differentiating prostate cancer from benign prostatic hyperplasia using whole-lesion histogram and texture analysis of diffusion- and T2-weighted imaging.
    Cancer Imaging. 2021;21:54.
    >> Share

    July 2021
  39. HE D, Wang X, Fu C, Wei X, et al
    MRI-based radiomics models to assess prostate cancer, extracapsular extension and positive surgical margins.
    Cancer Imaging. 2021;21:46.
    >> Share

    April 2021
  40. OSMAN MM, Iravani A, Hofman MS, Hicks RJ, et al
    Intra-patient comparison of physiologic (68)Ga-PSMA-11 and (18)F-DCFPyL PET/CT uptake in ganglia in prostate cancer patients: a pictorial essay.
    Cancer Imaging. 2021;21:35.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016